Mononuclear cell polyamine content associated with myeloid maturation in patients with leukemia during administration of polyamine inhibitors.
Fourteen patients with acute leukemia in relapse were treated with difluoromethylornithine (DFMO) alone or in combination with methylglyoxal-bis(guanylhydrazone) (MGBG) as part of Phase I studies. Five patients included in the trial exhibited morphologic evidence of cellular differentiation during the course of treatment. In one patient who exhibited no blasts and a normal white blood cell differential at the end of treatment the mononuclear cell content of all three polyamines declined after an initial increase in spermidine and spermine content. In the other patients in whom the cellular maturation was less pronounced the mononuclear cell polyamine levels remained stable or increased over the treatment time. No absolute difference was apparent between the cellular polyamine levels detected in patients at the times of the greatest increase in per cent circulating neutrophils as compared to the cellular levels present in patients whose circulating mononuclear cell number were increasing. Circulating mononuclear cell putrescine, spermidine, and spermine levels varied over two orders of magnitude from patient to patient and the range of values detected in each state completely overlapped those present in the other. It does not appear from the present study that there is a consistent human leukemic cell polyamine content at which cellular differentiation occurs.
Maddox
A M
AM
Division of Hematology/Oncology, University of Texas Medical School, Houston.
Keating
M J
MJ
Freireich
E J
EJ
Haddox
M K
MK
D000293:Adolescent; D000328:Adult; D000368:Aged; D015317:Biogenic Polyamines / Q000378:metabolism*; D001853:Bone Marrow / Q000187:drug effects / Q000378:metabolism; D001854:Bone Marrow Cells; D004341:Drug Evaluation; D000518:Eflornithine / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007938:Leukemia / Q000188:drug therapy* / Q000378:metabolism; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D008935:Mitoguazone / Q000009:adverse effects* / Q000627:therapeutic use; D009000:Monocytes / Q000378:metabolism*; D013997:Time Factors
D015317:Biogenic Polyamines; D008935:Mitoguazone; D000518:Eflornithine